Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.33 |
| ▸ | TUBB | P07437 | 5/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29525638 | 1.00 | KDM4E (0.52) | KDM4EALDH1A1MAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL11812707 | 0.87 | KDM4E (0.50) | KDM4EALDH1A1MAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL9736640 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1MAPK1SMN1; SMN2SLC2A1 | |
| Hydrochloric Acid SCHEMBL22778178 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1MAPK1SMN1; SMN2SLC2A1 | |
| SCHEMBL5424752 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1MAPK1SMN1; SMN2SLC2A1 | |
| SCHEMBL30106633 | 0.80 | CNR1 (0.33) | KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A | |
| SCHEMBL30106680 | 0.80 | CNR1 (0.33) | KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A | |
| SCHEMBL30106694 | 0.80 | CNR1 (0.33) | KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A | |
| Hydrochloric Acid SCHEMBL22778176 | 0.79 | KDM4E (0.50) | KDM4EALDH1A1MAPK1SMN1; SMN2SLC2A1 | |
| SCHEMBL14349080 | 0.79 | KDM4E (0.74) | KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279184-A1 | HETEROAROMATIC ANALOGUES OF 3-BENZYLMENADIONE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | UNIVERSITE DE HAUTE ALSACE (FR) | 2024-08-22 | — | — | US | disclosed |
| EP-3983385-B1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3983385-B1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230002324-A1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20230002324-A1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-3983385-A1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020252414-A1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252414-A1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002324-A1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | NFE2L2, AIFM2, GPX4 | KDM4E 4026/4885ALDH1A1 899/4885MAPK1 1753/4885 |
| US-20240279184-A1 | HETEROAROMATIC ANALOGUES OF 3-BENZYLMENADIONE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CYP1B1, CYP1A1, CYP2B6 | KDM4E 2880/4885ALDH1A1 524/4885MAPK1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.